ITCA 650 60 mcg/day

DRUG3 trials

Sponsors

Intarcia Therapeutics

Conditions

Type 2 Diabetes

Phase 3

A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

WithdrawnNCT01455883

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-02-28End: 2014-07-31Updated: 2012-12-25

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

WithdrawnNCT01455909

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-02-28End: 2014-07-31Updated: 2012-12-25

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

CompletedNCT01455870

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-05-31End: 2015-07-31Updated: 2016-06-02